Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 261

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 261
---
 loans bear 6% interest per annum. Of the aggregate $ 83,000Prophase July 2024 Loans, $ 30,000was due on September 14, 2024, $ 3,000was due on September 24, 2024 and $ 50,000was due on September 29, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. In August 2024, the Company borrowed an additional $ 50,000from Prophase (the “Prophase August 2024 Loans”). The loans bear 6% interest per annum. Of the aggregate $ 50,000Prophase August 2024 Loans, $ 30,000was due on October 12, 2024 and $ 20,000was due on October 13, 2024, all of which may be extended to the second anniversary upon mutual agreement of the parties. As of December 31, 2024 and 2023, the balance of the Prophase loans is

<div align='center'>F-48</div>

$ 1.6million and $ 0. For the years ended December 31, 2024 and 2023, interest expense related to the Prophase Loans was less than $ 0.1million and $ 0, respectively. See Note 5 for discussion related to notes which have passed their maturity dates. Hana Loans On August 1, 2024, the Company borrowed $ 0.9million from Hana Immunotherapeutics, LLC (“Hana”), a related party of the Company due to having common executives (the “Hana Loans”). The Hana Loans bear interest at 6% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties. As of December 31, 2024 and 2023, the balance of the Hana Loans is $ 0.9million and $ 0, respectively. For the years ended December 31, 2024 and 2023, interest expense related to the Hana Loans was less than $ 0.1million and $ 0, respectively. See Note 5 for discussion related to notes which have passed their maturity dates. Amantes Loans On November 1, 2024, the Company borrowed $ 0.4million from Amantes LLC (“Amantes”), a related